Abstract
Background Immune-mediated diseases (IMD) encompass a wide range of autoimmune and inflammatory disorders with aetiology related to immune system dysfunction, signifying a disease area with great potential for drug repurposing. In this study, we employed the genetically informed Mendelian Randomization (MR) method with two distinct exposure types: immune blood cell abundance and protein quantitative trait loci (pQTL) to validate and repurpose 834 drug targets which have been investigated for IMD treatment.
Methods Utilizing two-sample MR, we first established causal relationships between major peripheral immune cell types and 14 IMD. Robust associations, particularly with eosinophils, were confirmed across diseases such as asthma, eczema, sinusitis, and rheumatoid arthritis, revealing 59 high-confidence relationships. Intragenic variants associated with causal immune cell types were then extracted to create instruments for 371 existing IMD drug targets ("intermediate trait" MR). In parallel, we leveraged four large blood plasma protein QTL datasets to obtain complementary instruments for 361 targets ("pQTL" MR).
Results In the intermediate trait MR analysis, we identified 811 gene-IMD associations (p-value <0.05), 169 of which were supported by strong colocalisation evidence (PPH4 ≥ 0.8). In the pQTL MR analysis, we similarly found 841 protein-IMD associations (p-value <0.05), 83 of which were confirmed with colocalization. Comparison with a list of approved drugs indicated low sensitivities across disease outcomes for both exposure types (intermediate trait MR: 0.49 ± 0.23 SD, pQTL MR: 0.28 ± 0.12 SD).
Conclusions Drug targets identified in the pQTL and intermediate trait MR analyses show limited overlap (13%), presenting a comprehensive source of drug repurposing opportunities when the two approaches are combined.
Competing Interest Statement
T.R.G. receives funding from Biogen and GlaxoSmithKline for unrelated research.
Funding Statement
This work was funded by the UK Medical Research Council (MRC) as part of the MRC Integrative Epidemiology Unit (MC_UU_00032/03). This study was also supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
We accessed the following immune cell GWAS summary statistics via OpenGWAS (https://gwas.mrcieu.ac.uk/)[105]: ebi-a-GCST90002292, ebi-a-GCST004634, ebi-a-GCST90002380, ebi-a-GCST90002298, ebi-a-GCST004617, ebi-a-GCST90002382, ebi-a-GCST004614, ebi-a-GCST004608, ebi-a-GCST90002316, ebi-a-GCST90002389, ebi-a-GCST90002340, ebi-a-GCST90002394, ebi-a-GCST004626, ebi-a-GCST90002351, ebi-a-GCST004623, ebi-a-GCST90002399, ebi-a-GCST004620, ebi-a-GCST004624, ebi-a-GCST004613, ebi-a-GCST90002374. We accessed the following immune-mediated disease GWAS summary statistics via OpenGWAS (https://gwas.mrcieu.ac.uk/)[105]: ebi-a-GCST90014325, ebi-a-GCST006862, ebi-a-GCST004132, ebi-a-GCST004131, ieu-b-18, ebi-a-GCST90019016, ebi-a-GCST002318, ebi-a-GCST003156, ebi-a-GCST010681, ebi-a-GCST004133. We obtained the following immune-mediated disease GWAS summary statistics from FinnGen ver. 9 (https://www.finngen.fi/en/access_results)[39]: M13_ANKYLOSPON, J10_CHRONSINUSITIS, L12_ATOPIC and NHGRI-EBI GWAS Catalog (http://www.ebi.ac.uk/gwas)[106]: GCST90244787, GCST90027899, GCST90010715. UKBB pQTL dataset[55] was accessed via https://metabolomips.org/ukbbpgwas/, deCODE pQTL dataset[53] was accessed via https://www.decode.com/summarydata/, ARIC pQTL dataset[52] was accessed via http://nilanjanchatterjeelab.org/pwas/.
